Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma

  • Authors:
    • Surangkana Sanmai
    • Tanakorn Proungvitaya
    • Temduang Limpaiboon
    • Daraporn Chua‑On
    • Wunchana Seubwai
    • Sittiruk Roytrakul
    • Sopit Wongkham
    • Chaisiri Wongkham
    • Ongart Somintara
    • Sakkarn Sangkhamanon
    • Siriporn Proungvitaya
  • View Affiliations

  • Published online on: March 22, 2019     https://doi.org/10.3892/ol.2019.10185
  • Pages: 5275-5282
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pyruvate dehydrogenase kinase (PDK) is a Ser/Thr kinase that inactivates mitochondrial pyruvate dehydrogenase and serves a key role in aerobic glycolysis, which is a hallmark of cancer cells. The present study determined the PDK expression in cholangiocarcinoma (CCA) tissues and sera to evaluate their applicability as a biomarker for CCA. Using proteomic analysis, PDK was revealed to be the most overexpressed mitochondrial protein in CCA tissues. Then, the expression of PDK isoforms in CCA tissues was examined in 15 CCA cases by immunohistochemistry. The PDK3 isoform levels in the sera were measured using a dot blot assay for 39 patients with CCA, 20 patients with benign biliary disease and 19 healthy volunteers. The results revealed a 27‑fold overexpression of PDK3 in cancerous tissues when compared with adjacent non‑cancerous tissues. The immunohistochemical results demonstrated that the PDK1, 2 and 3, but not the PDK4, isoforms were overexpressed in cancerous tissues. When the PDK3 levels in the sera were examined, they were significantly higher in CCA when compared with the BBD and healthy groups. The specificity and sensitivity of PDK3 as a marker for CCA were 97.5 and 33.0%, respectively, and high PDK3 levels in the sera were correlated with a short survival time for CCA. In conclusion, PDK3 can be used as a diagnostic/prognostic marker for CCA.

References

1 

Khan SA, Toledano MB and Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 10:77–82. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM and Loukas A: The tumorigenic liver fluke Opisthorchis viverrini-multiple pathways to cancer. Trends Parasitol. 28:395–407. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Pattanapairoj S, Silsirivanit A, Muisuk K, Seubwai W, Cha'on U, Vaeteewoottacharn K, Sawanyawisuth K, Chetchotsak D and Wongkham S: Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach. Clin Biochem. 48:668–673. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Wongkham S and Silsirivanit A: State of serum markers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev. 13 (Suppl):S17–S27. 2012.

6 

Chua-On D, Proungvitaya T, Techasen A, Limpaiboon T, Roytrakul S, Wongkham S, Wongkham C, Somintara O, Sungkhamanon S and Proungvitaya S: High expression of apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3) in human cholangiocarcinoma. Tumour Biol. 37:13659–13667. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Icard P and Lincet H: A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta. 1826:423–433. 2012.PubMed/NCBI

8 

Saunier E, Benelli C and Bortoli S: The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int J Cancer. 138:809–817. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Bowker-Kinley MM, Davis WI, Wu P, Harris RA and Popov KM: Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 329:191–196. 1998. View Article : Google Scholar : PubMed/NCBI

10 

Mi H, Poudel S, Muruganujan A, Casagrande JT and Thomas PD: PANTHER version 10: Expanded protein families and functions, and analysis tools. Nucleic Acids Res. 44:D336–D342. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Dupont WD and Plummer WD Jr: Power and sample size calculations. A review and computer program. Control Clin Trials. 11:116–128. 1990. View Article : Google Scholar : PubMed/NCBI

12 

Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, Simon MS, Weiss LK, Malone KE, Burkman RT, et al: Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Br Cancer Res. 15:R902013. View Article : Google Scholar

13 

Tan LD, Xu YY, Yu Y, Li XQ, Chen Y and Feng YM: Serum HER2 level measured by dot blot: A valid and inexpensive assay for monitoring breast cancer progression. PLoS One. 6:e187642011. View Article : Google Scholar : PubMed/NCBI

14 

Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Jeoung NH: Pyruvate dehydrogenase kinases: Therapeutic targets for diabetes and cancers. Diabetes Metab J. 39:188–197. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, Ham IH and Han SU: Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 42:44–54. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Lim HY, Yip YM, Chiong E, Tiong HY, Halliwell B, Esuvaranathan K and Wong KP: Metabolic signatures of renal cell carcinoma. Biochem Biophys Res Commun. 460:938–943. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Lu CW, Lin SC, Chien CW, Lin SC, Lee CT, Lin BW, Lee JC and Tsai SJ: Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol. 179:1405–1414. 2011. View Article : Google Scholar : PubMed/NCBI

19 

Roh JL, Park JY, Kim EH, Jang HJ and Kwon M: Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Cancer Lett. 371:20–29. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Gudi R, Bowker-Kinley MM, Kedishvili NY, Zhao Y and Popov KM: Diversity of the pyruvate dehydrogenase kinase gene family in humans. J Biol Chem. 270:28989–28994. 1995. View Article : Google Scholar : PubMed/NCBI

21 

Lu CW, Lin SC, Chen KF, Lai YY and Tsai SJ: Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 283:28106–28114. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Petersen TN, Brunak S, von Heijne G and Nielsen H: SignalP 4.0: Discriminating signal peptides from transmembrane regions. Nat Methods. 8:785–786. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Sombattheera S, Proungvitaya T, Limpaiboon T, Wongkham S, Wongkham C, Luvira V and Proungvitaya S: Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice. Asian Pac J Cancer Prev. 16:1367–1370. 2015. View Article : Google Scholar : PubMed/NCBI

24 

Janan M, Proungvitaya S, Limpaiboon T, Proungvitaya T, Roytrakul S, Wongkham C, Jearanaikoon P, Chur-in S and Wongkham S: Serum adhesion molecule-1 (ICAM-1) as a potential prognostic marker for cholangiocarcinoma patients. Asian Pac J Cancer Prev. 13 (Suppl):S107–S114. 2012.

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sanmai, S., Proungvitaya, T., Limpaiboon, T., Chua‑On, D., Seubwai, W., Roytrakul, S. ... Proungvitaya, S. (2019). Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma. Oncology Letters, 17, 5275-5282. https://doi.org/10.3892/ol.2019.10185
MLA
Sanmai, S., Proungvitaya, T., Limpaiboon, T., Chua‑On, D., Seubwai, W., Roytrakul, S., Wongkham, S., Wongkham, C., Somintara, O., Sangkhamanon, S., Proungvitaya, S."Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma". Oncology Letters 17.6 (2019): 5275-5282.
Chicago
Sanmai, S., Proungvitaya, T., Limpaiboon, T., Chua‑On, D., Seubwai, W., Roytrakul, S., Wongkham, S., Wongkham, C., Somintara, O., Sangkhamanon, S., Proungvitaya, S."Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma". Oncology Letters 17, no. 6 (2019): 5275-5282. https://doi.org/10.3892/ol.2019.10185